Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptose Biosciences, Inc. - Common Shares (TSX:APS)

1.350 -0.050 (-3.57%)
Streaming Delayed Price Updated: 11:08 AM EDT, Jun 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,549
Open 1.420
Bid (Size) 1.340 (1)
Ask (Size) 1.560 (9)
Prev. Close 1.400
Today's Range 1.350 - 1.550
52wk Range 0.1550 - 5.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Provides Corporate Updates
From Aptose Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
+309.1%
+309.1%
1 Month
-42.8%
-42.8%
3 Month
-73.7%
-73.7%
6 Month
+280.3%
+280.3%
1 Year
+31.1%
+31.1%

More News

Read More
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Results from Annual and Special Meeting of Shareholders
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports First Quarter 2025 Results
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Auditor Not Standing for Re-Appointment
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Reports Year End 2024 Results and Corporate Highlights
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Reverse Share Split
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Positive Decision by Nasdaq Hearings Panel
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
From Aptose Biosciences, Inc.
Via GlobeNewswire
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
From Aptose Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Aptose Biosciences, Inc. - Common Shares publicly traded?
Yes, Aptose Biosciences, Inc. - Common Shares is publicly traded.
What exchange does Aptose Biosciences, Inc. - Common Shares trade on?
Aptose Biosciences, Inc. - Common Shares trades on the Toronto Stock Exchange
What is the ticker symbol for Aptose Biosciences, Inc. - Common Shares?
The ticker symbol for Aptose Biosciences, Inc. - Common Shares is APS on the Toronto Stock Exchange
What is the current price of Aptose Biosciences, Inc. - Common Shares?
The current price of Aptose Biosciences, Inc. - Common Shares is 1.350
When was Aptose Biosciences, Inc. - Common Shares last traded?
The last trade of Aptose Biosciences, Inc. - Common Shares was at 06/23/25 11:08 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.